436 related articles for article (PubMed ID: 12576817)
1. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
[TBL] [Abstract][Full Text] [Related]
2. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.
Shariat SF; Matsumoto K; Kim J; Ayala GE; Zhou JH; Jian W; Benedict WF; Lerner S
J Urol; 2003 Sep; 170(3):985-9. PubMed ID: 12913755
[TBL] [Abstract][Full Text] [Related]
3. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
[TBL] [Abstract][Full Text] [Related]
4. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
5. [Expression of cyclooxygenase-2 in human transitional cell bladder carcinomas].
Zhan J; Tang XD
Ai Zheng; 2002 Nov; 21(11):1212-6. PubMed ID: 12526218
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
7. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
Margulis V; Shariat SF; Ashfaq R; Thompson M; Sagalowsky AI; Hsieh JT; Lotan Y
J Urol; 2007 Mar; 177(3):1163-8. PubMed ID: 17296438
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
9. Expression of cyclooxygenase-2 in patients with bladder carcinoma.
Yoshimura R; Sano H; Mitsuhashi M; Kohno M; Chargui J; Wada S
J Urol; 2001 May; 165(5):1468-72. PubMed ID: 11342898
[TBL] [Abstract][Full Text] [Related]
10. Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract.
Miyata Y; Kanda S; Nomata K; Eguchi J; Kanetake H
J Urol; 2005 Jan; 173(1):56-60. PubMed ID: 15592025
[TBL] [Abstract][Full Text] [Related]
11. [Expression of cyclooxygenase in bladder transitional cell carcinoma].
Wang KJ; Li H; Wei Q; Yang YR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):54-6. PubMed ID: 14981815
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of nuclear p53 and tumor progression in bladder cancer.
Esrig D; Elmajian D; Groshen S; Freeman JA; Stein JP; Chen SC; Nichols PW; Skinner DG; Jones PA; Cote RJ
N Engl J Med; 1994 Nov; 331(19):1259-64. PubMed ID: 7935683
[TBL] [Abstract][Full Text] [Related]
13. Cox-2 and Her2/neu co-expression in invasive bladder cancer.
Eltze E; Wülfing C; Von Struensee D; Piechota H; Buerger H; Hertle L
Int J Oncol; 2005 Jun; 26(6):1525-31. PubMed ID: 15870865
[TBL] [Abstract][Full Text] [Related]
14. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma.
Rao J; Seligson D; Visapaa H; Horvath S; Eeva M; Michel K; Pantuck A; Belldegrun A; Palotie A
Cancer; 2002 Sep; 95(6):1247-57. PubMed ID: 12216092
[TBL] [Abstract][Full Text] [Related]
15. The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma.
Bernardini S; Billerey C; Martin M; Adessi GL; Wallerand H; Bittard H
J Urol; 2001 Jan; 165(1):42-6; discussion 46. PubMed ID: 11125360
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
[TBL] [Abstract][Full Text] [Related]
17. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder.
Fleshner N; Kapusta L; Ezer D; Herschorn S; Klotz L
J Urol; 2000 Oct; 164(4):1177-82. PubMed ID: 10992361
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
19. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
[TBL] [Abstract][Full Text] [Related]
20. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]